



IBA Selected to Install Proton Therapy System In Texas

- VALUE OF THE DEAL TO IBA IS APPROXIMATELY \$50 MILLION
- INCLUDES LONG-TERM OPERATIONS AND MAINTENANCE AGREEMENT

Louvain-la-Neuve, Belgium, September 07, 2012 - IBA (Ion Beam Applications S.A.), the global high-tech leader in the next generation of radiation therapy and diagnostics for the treatment of cancer, announces it has been selected to install and maintain a proton therapy system in a new facility in the Dallas area, which is planned to open in 2015.

The estimated value of the deal to IBA is approximately \$50 million and includes a set of 3 treatment rooms and advanced image guidance technology. A long-term operation and maintenance agreement is also included.

Dallas-based [Texas Oncology](#), supported by [McKesson Specialty Health](#); and Baylor Health Enterprises, an affiliate of [Baylor Health Care System](#), announced that Irving-Las Colinas has been chosen as the home for the \$105 million proton therapy facility in the heart of the Dallas-Fort Worth Metroplex. Proton therapy is an advanced form of radiation treatment, particularly effective in treating certain pediatric and adult cancers, often with fewer side effects.

Representatives expect construction to begin on the 50,000-square-foot proton therapy facility in 2013, and they anticipate the first patients will be treated in the advanced cancer treatment complex in late 2015. Final economic incentives are pending approvals later this month by Irving City Council and Dallas County Utility and Reclamation District.

Olivier Legrain, Chief Executive Officer of IBA commented, “We are delighted to be able to announce this deal as expected, which represents a significant revenue stream for IBA. The new center will be the 23rd international center using IBA’s next generation proton therapy equipment and we are committed to supporting this venture in providing high quality cancer treatment to more patients. We are confident in the positive outlook for the proton therapy sector and we remain focused on delivering several proton therapy contracts before the end of the year.”



“The proton therapy facility will provide our team of oncologists working across the state another critical tool in the fight against cancer,” **said Dr. Steven Paulson, Chairman and President of Texas Oncology.** “Bringing advancements like this into our community-based practice is a hallmark of our approach, which is centered around patients and making the most advanced tools and treatments available to them.”

“We have an extraordinary opportunity to bring leading cancer care technology that offers fewer side effects to more patients,” **said Marc Owen, president of McKesson Specialty Health,** a division of McKesson Corporation that supports The US Oncology Network. “And we’re going to do it by building a facility with leading technology and highly respected physicians and healthcare providers in the Dallas area. Proton therapy will bring a new level of community-based cancer care to patients.”

This innovative facility is being designed by RTKL Associates, part of the ARCADIS global network.

Notes for Editors

ABOUT IBA

IBA (Ion Beam Applications S.A.), is the global high-tech leader in next generation radiation therapy and diagnostics of cancer. The Company’s expertise lies in the development of next generation proton therapy technologies and radiopharmaceuticals that provide oncology care providers with premium quality services and equipment, including IBA’s leading fully integrated IntegraLab[®] radiopharmacy system, and Dosimetry advanced solutions for Quality Assurance of medical equipment and increased patient safety.

Headquartered in Belgium and employing more than 1,200 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors by providing solutions in the fight against cancer.

IBA is listed on the pan-European stock exchange EURONEXT. Further information can be found at: www.iba-worldwide.com

About the Collaboration

Texas Oncology, McKesson Specialty Health, and Baylor Health Enterprises, an affiliate of Baylor Health Care System, are collaborating to develop a proton therapy facility in the Dallas-Fort Worth Metroplex. The advanced treatment facility will provide services through Texas Oncology, an independent oncology practice based in Dallas with locations throughout Texas and southeastern Oklahoma, including the Baylor Charles A. Sammons Cancer



Center. Texas Oncology is a member of The US Oncology Network, which includes privately held community-based oncology practices across the country.

About Texas Oncology

Texas Oncology delivers high-quality cancer care with leading-edge technology and advanced treatment and therapy options available to help patients achieve “More breakthroughs. More victories.”[®] in their fights against cancer. Texas Oncology, a pioneer in community-based cancer care, is an independent oncology practice with sites of service throughout Texas and southeastern Oklahoma. Texas Breast Specialists and Texas Urology Specialists, which focus on all areas of breast and urologic care, are a part of Texas Oncology.

Texas Oncology patients have the opportunity to take part in some of the most promising clinical trials in the nation for a broad range of cancers. Texas Oncology participates in innovative clinical trials from Phase I through Phase IV through US Oncology Research, which has helped to develop 43 FDA approved cancer therapies.

For more information, visit www.TexasOncology.com or call 1-888-864-I CAN (4226).

About McKesson Specialty Health

[McKesson Specialty Health](http://www.mckessonsspecialtyhealth.com), a division of [McKesson Corporation](http://www.mckesson.com), empowers community patient care delivery systems by providing solutions to aid in the advancement of science, technology and quality of care. Through innovative clinical, research, business and operational solutions, facilitated by integrated technology systems, our products aim to improve the financial health of our customers so they may provide the best care for their patients. For more information, visit www.mckessonsspecialtyhealth.com.

For more information, please contact

IBA

Jean-Marc Bothy

Chief Financial Officer

Tel: +32 10 47 58 90

Texas Collaboration

Shana Bristow

214-665-1316

Press release |

Regulated information



Shana.Bristow@fleishman.com

or

Meredith Adams

214-665-1346

Meredith.Adams@fleishman.com

or

Jennifer Horspool

949-933-4300

Jennifer.Horspool@usoncology.com

For media and investor enquiries about IBA

M:Communications

Mary-Jane Elliott, Amber Bielecka, Claire Dickinson

+44 (0) 207 920 2333

IBA@mcomgroup.com